University of Groningen
Endovascular approaches to complex aortic aneurysms
de Niet, Arne
DOI:
10.33612/diss.111895510
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date: 2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
de Niet, A. (2020). Endovascular approaches to complex aortic aneurysms. University of Groningen. https://doi.org/10.33612/diss.111895510
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
CHAPTER
Mid- and long-term
outcome of currently
available endografts
for the treatment of
infrarenal abdominal
aortic aneurysm
Leonie T. Jonker Arne de Niet Michel M.P.J. Reijnen Ignace F.J. Tielliu Clark J. ZeebregtsSurgical Technology International, 2018;33:239-250
Ch
ap
ter 2
20
Abstract
Currently, there is a wide range of commercially available endografts for infrarenal abdominal aortic aneurysm (AAA) repair. Results of long-term follow up after endovascular aneurysm repair (EVAR) are limited. Thereby, the durability of these endografts and the difference between manufacturers is not fully clear.
In this review, studies with mid- and long-term results, with a minimum median follow up of 36 months per endograft, were included describing results with Cook Zenith® Flex® endograft (Cook Medical Inc., Bloomington, Indiana) (n=6), Cordis Corporate INCRAFT® (Cordis Corporation, Freemont, California) (n=1), Gore® EXCLUDER® (W.L. Gore & Associates Inc., Flagstaff, Arizona) (n=3), Medtronic Endurant™ (Medtronic plc, Santa Rosa, California) (n= 6), and Vascutek Anaconda™ (Vascutek Ltd., Inchinnan, Scotland) (n=2).
The assisted technical success varied between 83% and 100%, and the perioperative mortality, early reintervention, and early conversion rates were comparable for the studied endografts. At three-year follow up, the freedom from AAA-rupture and AAA-related death varied between 98% and 100%. The results demonstrated an increasing complication and reintervention rate over time. When adhering to the instruction for use, minor differences were seen during follow up between the endografts.
Latest generation endografts continue to have good postoperative results; the reinterventi-on-rate of 10–20% over time mandates an ongoing close patient follow up. The choice of a specific design depends on native patient anatomy and the experience of the implanting surgeon.
2
Introduction
Since Parodi et al.1 reported the concept of endovascular aneurysm repair (EVAR) in 1991,
EVAR increasingly became the preferred option for treatment of abdominal aortic aneurysm
(AAA). Currently, nearly 80% of all AAAs are treated by EVAR in the United States.2,3 EVAR
is associated with a lower perioperative mortality and morbidity and a shorter hospital stay
compared to open aneurysm repair (OAR).4-6 However, long-term survival rates seem to be
better for OAR, this is mainly attributed to secondary AAA rupture.7 Furthermore, EVAR
has been associated with a higher rate of secondary interventions and a significantly higher in-hospital cost of care compared to OAR.8-10
Over time, technological advances have improved the capacity of endografts to treat aortic AAAs. Improved fabrics, better scaffolding designs and materials, low-profile delivery systems, more precise deployment mechanisms, enhanced fixation, greater conformability, and diverse
modular components were developed and applied to newer generation endografts.11 Most
manufacturers of EVAR devices now produce their third-generation commercially available
endograft.12 These technological improvements, combined with increased surgical experience
and selection of patients within the specified instructions for use (IFU), led to higher
reinter-vention-free survival and higher freedom from aneurysm-related death after EVAR.11,13
Results of long-term follow up after EVAR are limited and the durability of endografts remains unclear. In this review, we describe mid- and long-term results of the latest-genera-tion endografts currently commercially available for treatment of infrarenal AAAs. Primary outcome parameters were overall survival, freedom from AAA-rupture, and AAA-related death, while a secondary outcome measure was freedom from reintervention.
Ch
ap
ter 2
22
Materials and methods
A PubMed search was performed with Medical Subject Headings (MeSH) terms including “Aortic Aneurysm, Abdominal/surgery” combined with “Aortic Aneurysm, Abdominal/ therapy” or “abdominal aneurysm” and “endovascular procedures” or endovascular”, “EVAR” and “follow-up”. All 1519 articles published in the English literature over a 10-year period (until January 2018) were screened for title and abstract. Additional searches were done adding for terms of the specific endografts and by cross-referencing. Reports of results of elective EVAR performed within the IFU, and with a currently available endograft, were eligible for inclusion. Studies with a minimum median follow up of 36 months were eligible for comparative analysis between endografts. If early results of the endograft were published previously, relevant data were obtained from that earlier report.
To review the applicability of the different endografts, primary and secondary outcome measures were compared according to the reporting standards of Chaikof et al. Primary technical success requires a successful introduction and deployment of the device in the absence of surgical conversion, mortality, type I or III endoleaks, or graft limb obstruction. It can include the use of planned additional modular components, angioplasty, and adjunctive surgical procedures. If unplanned endovascular procedures are necessitated, the term assisted primary technical success is used.14
Pooled analysis was done for primary and primary-assisted technical success, freedom from reintervention, overall-survival, freedom from AAArupture, and AAA-related death. Ka-plan-Meier analysis was used for survival analysis, but when not available, survival or freedom from events at median follow up was presented. Separately, adverse events during median follow up were collected, including endograft patency, limb occlusion, endograft migration, kinking, stentbody fracture, disconnection, endoleak, and freedom from reintervention. In most selected articles, conversion from EVAR to open surgical repair was reported as early (<30 days) or late (>30 days) conversion.14
2
Results
The inclusion criteria were met in 122 studies. Mid- and long-term results with a minimum median follow up of 36 months per endograft were reported in 18 studies—Cook Zenith® Flex® endograft (Cook Medical Inc., Bloomington, Indiana) (n=6), Cordis Corporate INCRAFT® (Cordis Corporation, Freemont, California) (n=1), Gore® EXCLUDER® (W. L. Gore & Associates Inc., Flagstaff, Arizona) (n=3), Medtronic Endurant™ (Medtronic plc, Santa Rosa, California) (n= 6) and Vascutek Anaconda™ (Vascutek Ltd., Inchinnan, Scotland) (n=2), all of which are discussed in detail below.
TABLE I: INSTRUCTION FOR USE FOR DISCUSSED ENDOGRAFTS Endograft Cook Zenith® SP
Flex® Cordis Corp INCRAFT® EXCLUDER®GORE® Endurant™ IIMedtronic Anaconda™Vascutek Prox LZ diam (mm) 18–32 20–27 19–32 19–32 17.5–31
Prox LZ length (mm) ≥15 ≥15 ≥15 10 15
Max LZ angle 60 NA ≤60⁰ ≤60⁰ ≤90⁰
Iliac LZ diam (mm) 7.5–20 9–18 8–25 8–25 8.5–21 Iliac LZ length (mm) ≥10 ≥10 ≥10 ≥15 ≥20 Fixation Suprarenal hooks Infra- and
transrenal hooks Infrarenal hooks Suprarenal hooks Infrarenal hooks Device Bifurcated with
iliac, 2x iliac extension Bifurcated with iliac, 2x iliac extension Bifurcated with iliac, 1x iliac extension Bifurcated with iliac, 2x iliac extension, proximal cuff extension Bifurcated short, 2x iliac extension
Delivery system Flexor Flexible Ultra-Low Profile
INCRAFT®
C3 Endurant II Anaconda Delivery system OD
(Fr) 18–22 14 12–18 14–20 20–23
Main body sheath
size OD (Fr) 18–22 14–16 16–18 18–20 20–23 Limb sheath size OD
(Fr) 12–16 12–13 12–15 14–16 18
Fabric Fabric (polyester woven) sewed into
stent Fabric (low-porosity woven polyester) over stent Fabric in stent, Low-permeable ePTFE and FEP
Fabric in stent, multifilament
polyester
Fabric in stent
Stent Stainless steel
Cook-Z Nitinol Nitinol Nitinol M-shaped Nitinol Fr=French size, OD=outer diameter, LZ=landing zone, Diam=diameter, ePTFE=expanded, polytetrafluoroethyle-ne, FEP=fluorinated ethylene propylene.
Ch
ap
ter 2
24
Zenith® Flex® AAA Endovascular Graft
The Cook Zenith® Flex® endograft is a three-part system consisting of a bifurcated aortic main-body and two iliac extensions (Figure 1a and b). The stainless-steel Z-stents are hand-sutured to a woven polyester graft material. The uncovered proximal stent has hooks to provide active suprarenal fixation. The design of the Zenith® Flex® graft has virtually remained unchanged since its introduction in 1997. The gaps of fabric between the stents were made wider to improve flexibility. The Zenith® Flex® promotes resistance to graft migration by proximal anchoring hooks and selfexpanding Z-stents which provide radial force and columnar strength by a long main-body design with stability and flexibility. IFU are shown in Table I. Long-term results of EVAR with Zenith® Flex® were reported in six papers.12,15-19
Figure 1a: The Cook Zenith® Flex® endograft.
2
30-day postoperative outcome
Only a few studies reported numbers for primary technical success (Table II). In the study by Greenberg et al., three of the 739 implantations of the Zenith® Flex® AAA endograft were aborted due to iliac artery morphology not appreciated before the procedure of which two were successfully treated by open repair and the third patient decided to have no further
intervention.15 Thirty-day mortality was 1–3%, mostly non-AAA-related. In the report by
Verzini et al., one of five perioperative deaths was due to AAA rupture.12 Freedom from
rein-tervention at 30 days was 93.4%.15,19
Mid- and long-term outcomes
Overall survival in all six papers was estimated by Kaplan-Meier analysis (Table II). Pooled analysis estimated an overall survival at eight years of 51.8%.12,18,19 Table III shows freedom
from AAA-rupture, AAA-related death, and reintervention. At 10-year follow up, Verzini et al. found an estimated overall survival of 37.8%, freedom from AAA rupture of 98.1%, freedom from AAA-related death of 97.3%, and freedom from late reintervention and conversion of 75.5%.12 Adverse events related to EVAR during follow up are listed in Table IV.
The INCRAFT® AAA Stent Graft is a three-piece modular bifurcated system (Figure 2a and b).
Figure 1b: The Cook Zenith® Flex® endograft after implantation on CT-angiography
Ch
ap
ter 2
26
Incraft® AAA stent graft
The graft is composed of nitinol circular Z-stents, with a low-porosity polyester graft covering the stents. The main-body has a short infrarenal sealing endoskeleton. For active suprarenal fixation, the endograft has eight to 10 proximal barbs. It has an ultra-low-profile delivery system (14 French outer diameter) to facilitate navigation in complex access anatomies such as tortuous and/or calcified iliac access vessels. The graft has the unique capability of in situ length adjustment up to 2–3cm bilaterally and an active locking mechanism between the main-body and limbs to minimize type III endoleaks. The INCRAFT® system comes with a limited number of device sizes and lengths but, because of its adjustable design, allows for treatment of a wide variety of anatomic variations. The INNOVATION trial is the first clinical, multicenter, prospective, nonrandomized study of the INCRAFT® system that included 60 patients.20-22 The IFU during the INNOVATION trial are shown in Table I.
30-day postoperative outcome
Primary technical success was 90%. At the end of the procedure, 55 of 60 patients (92%) had absence of type I or III endoleak. One patient required a proximal aortic cuff for correction of a type Ia endoleak intraoperatively. Mortality at 30 days was 0% and freedom from reinterventi-on at 30 days was 100%.
Mid- and long-term outcomes
Overall survival at one and two year follow up is shown in Table II. With a median follow up of 48 months, a total of 9/60 patients died in four years, and no death was AAA or device related.22 Adverse events during follow up are shown in Table IV.
2
Figure 2b: The INCRAFT® AAA stent graft after implantation on CT-angiography.
Gore® EXCLUDER® AAA Endoprosthesis
The Gore® EXCLUDER® is a twomodular system consisting of a bifurcated endograft with a standard ipsilateral and a separate contralateral iliac extension (Figure 3a and b). Presently, the endograft consists of low permeability expanded polytetrafluoroethylene (ePTFE) and fluorinated ethylene propylene (FEP). The endograft is externally supported by nitinol stents to which it is attached by a bonding film rather than through sutures. Active infrarenal fixation is accomplis-hed by circumferential nitinol anchors and a proximal sealing cuff without suprarenal fixation. The new C3 delivery system, in use since 2010, made it possible to reposition the endograft after deployment by a constrai-ning wire at the top of the endograft. The low permeabi-lity Gore® EXCLUDER® differs from the original Gore® EXCLUDER® Endoprosthesis by the addition of film
layers that decrease the overall permeability of the graft. The IFU are shown in Table I. The results of the Gore® EXCLUDER®, with a median follow up over 36 months, were described in three papers.
30-day postoperative outcome
Pooled analysis shows a primary technical success of 95.9%.23-26 In the series described by Bos
et al., two patients had a type Ia endoleak at completion angiography. One was successfully corrected with a proximal extension. In the second patient, a small proximal endoleak was accepted after ballooning in a 50mm long neck and it spontaneously resolved at one-month follow up.25 Bastos Goncalves et al. needed to convert to open repair in 1/144 patients due to
inadvertently low deployment. Additional intraoperative endovascular procedures (including ballooning) were necessary in 22/144 patients: for a type Ia endoleak (n=17), type Ib endoleak (n=2), and for partial occlusion of a renal artery (n=4). The exact mechanism of partial renal occlusion was not specified.26 Mortality at 30 days was 0–1.4% and freedom from reinterven-tion at 30 days was 97.2–98.9%.25,26
Ch
ap
ter 2
28
Mid- and long-term outcomes
Overall survival is shown in Table II.24-26 Bos
et al. reported six out of 20 deaths, classified as indeterminate AAArelated, but no AAA rupture was diagnosed in five years of follow up.25 Bastos Goncalves et al. estimated a freedom
from AAA-related mortality of 96.6%.26 At 10
years follow up, Pratesi et al. had an overall survival of 62.5% and an estimated freedom from AAA-related mortality of 97.2%.24 Freedom from reintervention is shown in Table III. Open reinter-vention was necessary in 2.7% of the cases. Addi-tionally, Pratesi et al. found a freedom from rein-tervention at five, seven, and 10 years of 87.7%, 82.4%, and 80.6, respectively. Table IV shows the main reasons for reintervention during follow up.
Figure 3b: The Gore® EXCLUDER® after implantation on CT-angiography.
2
The Endurant™ Stent graft
The Endurant™ II consists of a three-piece modular system with M-shaped nitinol stents secured to high density polyester (Figure 4a and b). Suprarenal fixation hooks were designed to compensate for the decreased columnar strength. The second-generation device (Endurant™ II stent graft) was improved with a lower-profile delivery system and longer limb lengths to accommodate a wider range of anatomical variations. Better delivery system visualization was accomplished by adding radio opaque markers to the endograft. IFU are shown in Table I. Mid- and long-term results of the Medtronic Endurant™ were reported in six articles with a minimum median follow up of 36 months.27-32 Out of 897 patients included in the articles, 99
patients were treated outside the IFU.
30-day postoperative outcome
Pooled primary and primary-assisted technical success were 96.3% and 99.2%, respectively. Two additional stent placements in a renal artery were required and one unplanned aorto-iliac
device was placed. There were no primary type I or III endoleaks or conversions.27,33 The
device could not be implanted in one patient due to stenotic iliac vessels, and the procedure was terminated.28 The single technical device failure in the series described by Singh et al.
was due to an inability to cannulate a contralateral gate that was collapsed in a narrowed distal aorta and, essentially, this created a monoiliac device
which was completed by a femoro-femoral crossover
bypass.30 In addition to procedures to resolve endoleaks,
9.2% of the patients in Mannetje et al.’s report required an iliac artery intervention, either to allow device implantation
or to optimize the end result on completion angiography.31
One failure was secondary to unintentional coverage of both renal arteries leading to renal artery occlusion and, in another, the Endurant™ endograft was not inserted due to unsuitable anatomy at the time of the index procedure.32
Pooled 30-day-mortality was 1.6%. One patient rejected further treatment after an unsuccessful embolectomy of an
Ch
ap
ter 2
30
iliac obstruction and died within 30 days. Another patient died within 30 days because of gastro-intes-tinal bleeding during heparin therapy for an arterial occlusion of the leg.27,33 Freedom from reintervention
within 30 days was 96.9%.
Mid- and long-term outcomes
Reported overall survival is shown in Table II. Table III shows the freedom from AAA-rupture and AAA-related death estimated by three studies. Zandvoort et al. reported three (3%) AAArelated deaths, all in the first year of follow up. Survival rates for patients treated within IFU were comparable to survival rates for those treated outside IFU.27 Bisdas et
al. had an overall mortality of 29% at median follow up of 42 months, with a known cause of death in 68/78
Figure 4b: The Endurant™ II after implantation on CT-angiography
patients.28 One death was AAA related. In Oliveira et al.’s report, late AAA rupture occurred in
two patients (3.1%), and this resulted in the death of one patient.29 Freedom from
reinterven-tion and the main reasons for reintervenreinterven-tions are menreinterven-tioned in Tables III and IV.
The Anaconda™ AAA stent graft system
The Anaconda™ is a three-piece modular graft system (Figure 5a and b). The graft material is made of woven polyester. The main-body consists of two proximal nitinol rings for proximal seal, with four pairs of proximal hooks for infrarenal fixation. The body below these rings is unsupported by stents allowing them to be placed in a more angulated infrarenal aorta. The limbs have an independent ring design and cannulation of the contralateral limb is facilitated by the ONE-LOK™ (Sigma Corporation, Kawasaki, Japan) magnet system. The delivery system has the ability to reposition the proximal main-body. IFU are shown in Table I. Mid- and long-term results of EVAR with Vascutek Anaconda™ were reported in two papers with a follow up of 36 and 40 months.
2
30-day postoperative outcome
Rödel et al. achieved a technical success of 83% in patients with
a mean proximal AAA neck angulation of 82˚.34 In one patient,
conversion to open repositioning was necessary because of an improperly released main-body below the aortic neck angulation due to an aortic rim. Because of unsuccessful contralateral iliac leg deployment in an already-deployed Anaconda™ mainbody, one patient needed a femorofemoral crossover bypass additional to an aortouni-iliac endovascular graft . Furthermore, there were four (6.7%) cases with a type Ia and Ib endoleak at fi nal angiography. Freyrie et al. compared the midterm results of 65 patients with severe neck angulation (Group A, GA: ≥60˚) with
737 patients with nonangulated necks (Group B, GB: <45˚).35
Th e endograft main-body was repositioned in 35% and 20.7% of cases, respectively, but this did not result in a diff erence in type Ia endoleaks occurrence (GA 1.5% vs. GB 1.3%) or conversion to open repair (GA 3% vs. 0.6%). Mortality at 30 days was 0–1.5%, and freedom from reintervention at 30 days was 97–99.7%.
Mid- and long-term outcomes
In the report of Freyrie et al., a follow up of 36 months was achieved in 14 patients in GA and in 120 patients in GB.35 Overall survival at three
years showed no statistically signifi cant diff erence in survival between treatment of angulated versus non-angulated necks (Table III). None of the deaths were AAA related. In total, 18/838 (2.1%) patients needed open AAA repair during follow up. Complications of endovascular treatment of AAA during follow up are mentioned in Table IV.
Figure 5a: Th e Anaconda™ AAA stent graft .
Figure 5b: Th e Anaconda™ AAA stent graft aft er implantation on CT-angiography.
Ch ap ter 2 32 TAB LE II THIR TY -D AY POS TO PER ATIVE O UT C O ME P ER END O GR AFT . Ea rly o pen co nv er sio n (%) 0.3 0.3 0.3 0.0 - 0.0 0.5 0.0 0.0 0.4 0.0 0.7 - 0.6 0.0 0.0 0.0 3.3 - 0.0 0.9 - b3 0.6 c Po ole d a na lysi s o f t he p os to pera tiv e r es ul ts p er en dog ra ft, minim al f ol lo w u p o f 36 m on th s. S om e o f t he e ar ly r es ul ts w er e o bt ain ed f ro m e ar lier p ub lic at io ns o f t he s tudies. 20-23,33,49,50 - D at a n ot a va ila ble , a P rim ar y t ec hnic al s ucces s o f 872 p at ien ts r ep or te d b y t he e ar ly s tud y r es ul ts in P ra tesi , 2014. 23 b Of a t ot al o f 65 p at ien ts w ith m edi an f ol lo w u p <36 m on th s. c Of a t ot al o f 737 p at ien ts w ith a m edi an f ol lo w u p <36 m on th s. GA: G ro up A n ec k a ngu la tio n ≥60˚, GB: g ro up B n ec k a ngu la tio n <45˚ Fr ee do m f ro m rein ter ven tio n 30 da ys (%) 93.4 97.1 - - - 94 - 100.0 100.0 97.9 98.9 97.2 - 96.9 - 96 - 98.7 96.8 97 99.1 98.3 b97 99.6 c 30-d ay M or ta lit y (%) 1.6 0.8 3.0 0.9 - 1.4 0.8 0.0 0.0 0.9 0.0 1.4 - 1.6 2.0 - 3.1 0.0 1.5 2.2 1.0 0.0 1.5 b 1.3 c A ssi ste d p rim ar y te chnic al s ucces s (%) 99.9 99.5 - - - 100.0 - 92.0 92.0 99.1 98.9 99.3 - 99.2 100.0 99.7 100.0 99.3 97.7 98.9 83.0 83.0 - -Pr im ar y t ec hnic al succes s (%) 99.8 - - 99.7 100.0 - - 90.0 90.0 95.9 97.8 89.6 97.5 a 96.3 98.0 - 98.5 - 93.8 - 83.0 83.0 - -N o. o f pa tien ts 68.5 60 54 51.6 66.4 40 99.2 48 48 79.6 36 60 94.4 44.9 48 42 52 42 59.2 37 36.2 40 36 36 N o. o f pa tien ts 1737 105 279 318 143 282 610 60 60 697 92 144 461 897 100 273 65 150 131 178 170 36 14 120 Pu blic at io n ye ar 2008 2009 2010 2011 2012 2017 2017 2009 2012 2018 2014 2014 2015 2016 2017 2017 2014 2014 2014 Fir st a ut ho r C oo k Z eni th® S P Flex® Gr ee nb erg 15 D ias 16 Fo rb es 17 M er ten s 18 Vä är äm äk i 19 Verzini 12 C or di s C or p IN CR AFT® Pra tesi 20-22 GO RE® EX CL UD ER® Bos 25 Ba stos G on ca lv es 26 Pra tesi 23,24 M ed tro nic En dura nt™ Za nd vo or t 27,33 Bis das 28 O liv eira 29, 49 Si ng h 30,50 M ann et je 31 D eer y 32 Va sc ut ek A naco nd a™ Rö del 34 Fr ey rie 35 (GA≥60˚) Fr ey rie 35 (GB<45˚)
2
TAB LE III: AND L O N G-TERM O UT C O MES P ER END O GR AFT . O vera ll S ur vi va l Fr ee do m f ro m AAA -r up tur e Fr ee do m f ro m AAA -r el at ed dea th Fr ee do m f ro m r e-in ter ven tio n Fir st a ut ho r N o. o f pa tien ts M edi an FU (m) 1 y ea r (%) 3 y ea r (%) 5 y ea r (%) 1 y ea r (%) 3 y ea r (%) 5 y ea r (%) 1 y ea r (%) 3 y ea r (%) 5 y ea r (%) 1 y ea r (%) 3 y ea r (%) 5 y ea r (%) C oo k Z eni th® S P Flex 1737 68,5 93.1 80.8 70.0 99.9 99.7 99.2 98.5 97.9 97.6 94.5 84.4 82.6 Gr ee nb erg 4 2008 105 60 94.5 81.6 77.6 99.9 99.9 99.9 98.1 97.5 97.5 90.2 82.5 79.3 D ias 16 2009 279 54 92 80 67 100* 99.3* -97 96 96 92 84 77 Fo rb es 17 2010 318 51,6 94 85 76 100* 100* 100* -M er ten s 18 2011 143 66.4 93.6 81.5 72.1 100 100 98.1 -90.7 83.5 77.1 Vä är äm äk i 19 2012 282 40 93 74 62 -93 86 81 Verzini1 3 2017 610 99.2 92.8 81.8 70.1 99.8 99.6 99.4 99.2 98.8 98.4 98 -87.7 C or di s C or p IN CR AFT® 60 48 98.2* 88.3* 100* 100* . 100* 100* Pra tesi 20-22 2017 60 48 98.2* 88.3* -100* 100* -100* 100* -GO RE® EX CL UD ER® 697 79,6 95.4 84.6 73.5 99.5* 99.2* 97.6 97.6 97.4 91.9 87.6 Bos 25 2009 92 36 95.2 83.9 70.2 100* 100* 100* -95 87 87 Ba stos G on ca lv es 26 2012 144 60 93 79 62 -97.6 -97.6 -73* Pra tesi 23,24 2018 461 94.4 96.2 86.5 77.7 99.4* 99* 99* -97.9 92.9 87.7 M ed tro nic En dura nt™ 897 44,9 93.0 81.4 72.5 100 99.6 99.2 99.1 99.0 98.5 94.5 91.8 84.8 Za nd vo or t 27,33 2014 100 48 88 82 -98 85 -Bis das 28 2014 273 42 90 77 67 -95.2 93 87 O liv eira 29, 49 2015 65 52 -83.1* -66.2* Si ng h 30,50 2016 150 42 96 89.1 82.3 100 99.2 99.2 100 99.2 99.2 95.3 91.6 89 t M ann et je 31 2017 131 59,2 93 -72.7 -98.4 -97.6 89.3 -75.2 D eer y 32 2017 178 37 98 87* -100 100 -98.9 98.9 -94* 93.8 -Va sc ut ek A naco nd a™ 36 36,2 97.0* 94.8 . 100* 98.4* 100* 100* 89.0* 80.0* Rö del 34 2014 36 40 97.0* 91.7* -100* 100* -89.0* 80.0* -Fr ey rie 35 (GA≥60˚) 2014 14 36 -95.4 -100* 85* -100* -Fr ey rie 35 (GB<45˚) 2014 120 36 -94.7 -100* 100* -100* -Po ole d a na lysi s p er en dog ra ft f ro m K ap la n-M eier s ur vi va l a na lysi s d at a. * S ur vi va l o r f re edo m f ro m e ven t a t m edi an f ol lo w u p o f t he s tud y (a s r ep or te d in t he f our th co lumn).- D at a n ot a va ila ble . GA: G ro up A n ec k a ngu la tio n ≥60˚, GB: g ro up B n ec k an gu la tio n <45˚Ch ap ter 2 34 TAB LE IV : T O TAL AD VERS E E VENT S P ER END O GR AFT D URIN G MED IAN FO LL O W -UP Lat e co nv er sio n (%) 0.02* 1.4 0.6 3.5 0.4 1.8 0.0 3.3 4.9 2.0 0.0 0.7 0.0 0.0 - 0.0 11.0 7.1 0.8 Po ole d d at a o f t ot al ad ver se e ven ts d ur in g m edi an f ol lo w u p p er a rt ic le. G re en ber g et a l. wa s t he o nl y s tud y c alc ul at in g t he f re edo m f ro m a n ad ver se e ven t a t e ac h y ea r o f f ol lo w up u sin g K ap la n-M eier a na lysi s. Th er ef or e, t he r es ul ts a re r ep or te d in t he t ab le b ut n ot in clude d in t he p oo le d a na lysi s. * K ap la n M eier s ur vi va l a na lysi s. GA: G ro up A n ec k an gu la tio n ≥60˚, GB: g ro up B n ec k a ngu la tio n <45˚ rAAA (%) 1.4 0.1* 1.4 0.0 4.2 0.7 1.1 0.0 0.0 2.7 0.0 0.7 0.6 0.3 0.0 0.4 3.1 0.7 0.8 0.0 3.5 2.8 7.1 0.0 En do le ak typ e III (%) 1.2 0.0* - 0.0 2.8 0.4 2.5 0.0 0.0 0.5 0.0 0.0 - 0.6 0.0 0.3 0.0 0.0 2.4 0.0 1.2 0.0 0.0 0.8 En do le ak typ e I (%) 1.5 0.0* - 2.5 12.6 5.0 9.4 0.0 6.7 0.0 3.3 12.0 - 0.4 7.0 2.0 16.9 2.0 7.1 1.1 0.6 11.1 0.0 1.6 Di sco nn ec tio ns (%) 7.2 0.1* - 0.0 2.1 0.0 - 6.7 0.0 8.5 0.0 1.4 0.0 4.2 - 0.0 0.0 0.0 0.8 0.0 3.5 0.0 0.0 0.0 St en t b od y frac tur es (%) 0.4 0.03* - 0.0 4.2 0.0 - 0.0 1.7 0.3 0.0 0.0 0.0 0.1 - 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Kin kin g (%) 0.8 - - - - 0.7 - 1.7 0.0 0.0 0.0 0.0 0.0 0.0 - 0.0 0.0 0.7 0.0 0.6 0.0 5.6 0.0 0.0 M ig ra tio n (%) 1.0 0.07* - 0.0 - 1.1 1.1 0.0 0.0 0.0 2.2 0.0 0.9 0.3 - 1.0 0.0 0.0 0.0 0.0 1.2 2.8 0.0 0.0 Lim b occ lu sio n (%) 0.8 0.03* - 0.6 5.6 2.8 3.4 0.0 5.0 0.9 0.0 14 1.3 0.3 4.0 4.0 10.8 3.3 5.6 3.4 0.6 14.0 0.0 0.8 M edi an FU (m) 2.8 60 54 51.6 66.4 40 99.2 5.0 48 1.2 36 60 94.4 4.5 48 42 52 42 59.2 37 3.5 40 36 36 n= 69 105 279 318 143 282 610 48 60 79.6 92 144 461 44.9 100 273 65 150 131 178 36.2 36 14 120 Pu blic at io n ye ar 1632 2008 2009 2010 2011 2012 2017 60 2017 697 2009 2012 2018 897 2014 2014 2015 2016 2017 2017 170 2014 2014 2014 Fir st a ut ho r, y ea r C oo k Z eni th® S P Flex Gr ee nb erg 4 D ias 16 Fo rb es 17 M er ten s 18 Vä är äm äk i 19 Verzini 13 C or di s C or p IN CR AFT® Pra tesi 20-22 GO RE® EX CL UD ER® Bos 25 Ba stos G on ca lv es 26 Pra tesi 23,24 M ed tro nic En dura nt™ Za nd vo or t 27,33 Bis das 28 O liv eira 29, 49 Si ng h 30,50 t M ann et je 31 D eer y 32 Va sc ut ek A naco nd a™ Rö del 34 Fr ey rie 35 (GA≥60˚) Fr ey rie 35 (GB<45˚)
2
Discussion
This review describes the results of the latest generation of currently available endografts for EVAR after a mid- and long-term outcome of 36 months of follow up.
The latest generation endografts are more flexible and low-profile.36 There have also been
improvements for more controlled deployment and easier catheterization.37 The IFU are
different for every specific type of endografts and help the clinician to choose the best available endograft for the treatment of a patient with an infrarenal AAA.
The current analysis showed comparable results between the endografts. The periopera-tive mortality, early reintervention, and early conversion rates were very low in all studied endografts, while the primary-assisted technical success varied between 83% and 100%. The latter appears to be lower in the Anaconda™ graft, potentially related to a higher incidence of type Ia endoleaks due to the stent design that needs more time to fully expand. Adhering to the IFU has led to good mid- and long-term clinical outcomes in all endografts. At three-year follow up, the freedom from AAA rupture and AAA-related death varied between 98% and 100%. The results, however, still demonstrate a significant complication and reinterven-tion rate after EVAR, mainly occurring during the first three years after initial treatment. Although newer generation endografts are used, this reintervention rate of 10–20% indicated the ongoing need for long-term follow up.38-40
Long-term results of follow up of the current endografts with the newest adjustments are still awaited. Because the design and delivery system of the Zenith® Flex®, Gore® EXCLUDER®, and the Medtronic Endurant™ II endografts have been virtually left unchanged, we chose to present longterm results of the latest available version.
The reviewed studies did not all specify the specific type of Zenith® Flex® endograft. Mertens et al. included the use of the older custom-made two-part design of Zenith® Flex®, which they used for the first two years of the study. The remaining studies described the Standard Profile, which is currently called Zenith® Flex® The Z-track introduction system, which was approved by the Food and Drug Administration (FDA) in 2008, was not specifically mentioned in the studies included in this review. The recently approved Cook Zenith® Low-Profile (Cook Medical Inc., Bloomington, Indiana) has similar outcomes to the Zenith® Standard-Profile (SP) (Cook Medical Inc., Bloomington, Indiana) endograft, despite being used to treat more patients with unfavorable iliac anatomy.41 There are no long-term follow up results of this
Ch
ap
ter 2
36
particular modification available.
In 2004, the Gore® EXCLUDER® with low permeability (LP) was introduced. Bos et al. used LP endografts in 38/92 (41%) and Bastos Goncalves in 83/144 (58%) of the patients. Pratesi et al. did not specify the permeability of the used endografts. Multiple studies have demon-strated a greater shrinkage rate of the AAA sac in using LP grafts compared to the older design with original permeability (OP).26,42-44 Additionally, in 2010, the C3 delivery system
was introduced. The reviewed studies did not use the C3 delivery system, which included the possibility for repositioning. In one study, with a large patient cohort of 200 cases, technical success was achieved in 196 cases (98%) where endograft repositioning was used in 45%, mostly for adjustment to the renal artery. Adverse events related to repositioning were noticed in three cases, but they were repaired by endovascular means. Overall, survival at one and three years was 97.2% and 89.6%, respectively. No migration, type I/III endoleaks, or limb occlusion were detected during median follow up of 17.8 months. Estimated freedom from reintervention was 92.4 at one year and 89.9 at three years.45
Not included in this review are the results of The Global Registry for Endovascular Aortic Treatment (GREAT). This is a prospective observational multicenter cohort registry that enrolled 3166 patients receiving a Gore® EXCLUDER® endograft for treatment of an infrarenal AAA from January 2011 to January 2017.46 The five-year follow-up results were only published
in May 2018, which was outside the searching criteria for selecting studies for this review. Howard et al. reported a technical success in 99.9% of cases. Freedom from reintervention was 93.7% at one year and 83.2% at five years. Five-year survival was 64.4% in the group with a large proximal aortic neck (≥25mm) and 76.5% in the group with a normal baseline proximal aortic neck (<25mm).47
In 2012, the FDA approved the Medtronic Endurant™ II. Compared to the older Medtronic Endurant™ I design, it includes a lower-profile delivery system, longer limb lengths, and better delivery system visualization. No longterm follow-up study has been published yet, but good short-term results seem to reflect the changes in design.
Comparing the results of the INCRAFT® and Vascutek Anaconda™ with the other endografts is difficult because of the few published studies with a median follow up over 36 months. During the first years, there was a tendency to perform EVAR in higher risk patients. Although, for this study, only articles were selected that were published in the past 10 years, and they likely included higher risk cases which may have led to selection bias.48 Most (15/18)
2
studies are prospective nonrandomized controlled design studies or retrospective analyses of prospective databases. Each clinician has its own preferences and experience, consequently influencing the choice to use a specific endograft. When interpreting outcomes from retros-pective data, this selection bias might influence the results. When strictly adhering to IFU, this bias can be minimized, but a randomized control trial with long-term follow up would show the true difference between available endografts for infrarenal AAA repair.
Conclusion
Currently, there is a wide range of commercially available endografts for infrarenal abdominal aortic AAA repair. The long-term results of these devices are not fully clear but have possibly improved with the introduction of newer generation endografts for infrarenal AAA repair. Nevertheless, given the differences in stent and graft design, each endograft will need to prove its own long-term efficacy. This review provides an overview of long-term results and the implications of choosing one of these latest generation endografts.
Ch
ap
ter 2
38
1.Parodi JC, Palmaz JC, Barone HD. Transfemoral intraluminal graft implantation for abdominal aortic aneurysms. Ann Vasc Surg 1991;5:491–9.
2.Buck DB, van Herwaarden JA, Schermerhorn ML, et al. Endovascular treatment of abdominal aortic aneurysms. Nat Rev Cardiol 2014;11:112–23.
3.Dua A, Kuy S, Lee CJ, et al. Epidemiology of aortic aneurysm repair in the united states from 2000 to 2010. J Vasc Surg 2014; 59:1512–7.
4.United Kingdom EVAR Trial Investigators, Greenhalgh RM, Brown LC, et al. Endovascular versus open repair of abdominal aortic aneurysm. N Engl J Med 2010;362: 1863–71.
5.Prinssen M, Verhoeven EL, Buth J, et al. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. N Engl J Med 2004;351: 1607–8.
6.Lederle FA, Freischlag JA, Kyriakides TC, et al. Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med 2012;367: 1988–97.
7.Schermerhorn ML, Buck DB, O’Malley AJ, et al. Long-term outcomes of abdominal aortic aneurysm in the medicare population. N Engl J Med 2015;373:328–38. 8.Blankensteijn JD, de Jong SE, Prinssen M, et al. Two-year outcomes after conventional or endovascular repair of abdominal aortic aneurysms. N Engl J Med 2005;352: 2398–405.
9.De Bruin JL, Baas AF, Buth J, et al. Longterm outcome of open or endovascular repair of abdominal aortic aneurysm. N Engl J Med 2010;362:1881–9.
10.Dangas G, O’Connor D, Firwana B, et al. Open versus endovascular stent graft repair of abdominal aortic aneurysms: A meta-analysis of randomized trials. JACC Cardiovasc Interv 2012;5:1071–80.
11.Tadros RO, Faries PL, Ellozy SH, et al. The impact of stent graft evolution on the results of endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014;59: 1518–27.
12.Verzini F, Romano L, Parlani G, et al. Fourteen-year outcomes of abdominal aortic endovascular repair with the Zenith stent graft. J Vasc Surg 2017;65:318–29. 13.Faries PL, Briggs VL, Rhee JY, et al. Failure of endovascular aortoaortic tube grafts: A plea for preferential use of bifurcated grafts. J Vasc Surg 2002;35:868–73.
14.Chaikof EL, Blankensteijn JD, Harris PL, et al.
Reporting standards for endovascular aortic aneurysm repair. J Vasc Surg 2002;35:1048–60.
15.Greenberg RK, Chuter TAM, Cambria RP, et al. Zenith abdominal aortic aneurysm endovascular graft. J Vasc Surg 2008; 48:1–9.
16.Dias NV, Riva L, Ivancev K, et al. Is there a benefit of frequent CT follow up after EVAR? Eur J Vasc Endovasc Surg 2009; 37:425–30.
17.Forbes TL, Harris JR, Lawlor DK, et al. Midterm results of the Zenith endograft in relation to neck length. Ann Vasc Surg 2010;24:859–62.
18.Mertens J, Houthoofd S, Daenens K, et al. Long-term results after endovascular abdominal aortic aneurysm repair using the cook Zenith endograft. J Vasc Surg 2011; 54:48–57.
19.Väärämäki S, Suominen V, Pimenoff G, et al. Long-term experience of endovascular aneurysm repair with Zenith prosthesis: Diminishing graft-related complications over time. Ann Vasc Surg 2012;26:845–51. 20.Torsello G, Scheinert D, Brunkwall JS, et al. Safety and effectiveness of the INCRAFT AAA stent graft for endovascular repair of abdominal aortic aneurysms. J Vasc Surg 2015;61:1–8.
21.Scheinert D, Pratesi C, Chiesa R, et al. First-in-human study of the INCRAFT endograft in patients with infrarenal abdominal aortic aneurysms in the INNOVATION trial. J Vasc Surg 2013;57:906–14. 22.Pratesi G, Pratesi C, Chiesa R, et al. The INNOVATION trial: Four-year safety and effectiveness of the INCRAFT(R) AAA stentgraft system for endovascular repair. J Cardiovasc Surg (Torino) 2017;58:650–57. 23.Pratesi C, Piffaretti G, Pratesi G, et al. Italian excluder registry and results of Gore Excluder endograft for the treatment of elective infrarenal abdominal aortic aneurysms. J Vasc Surg 2014;59:52–7.
24.Pratesi G, Piffaretti G, Verzini F, et al. Ten-year outcome analysis of the Italian Excluder registry with the Gore Excluder endograft for infrarenal abdominal aortic aneurysms. J Vasc Surg 2018;67:740–46. 25.Bos WT, Tielliu IF, Van Den Dungen JJ, et al. Results of endovascular abdominal aortic aneurysm repair with selective use of the Gore Excluder. J Cardiovasc Surg (Torino) 2009;50:159–64.
26.Bastos Goncalves F, Jairam A, Voute MT, et al. Clinical outcome and morphologic analysis after endovascular aneurysm repair using the Excluder endograft. J Vasc Surg 2012;56:920–28.
2
27.Zandvoort HJA, Goncalves FB, Verhagen HJM, et al. Results of endovascular repair of infrarenal aortic aneurysms using the Endurant stent graft. J Vasc Surg 2014;59: 1195–202.
28.Bisdas T, Weiss K, Eisenack M, et al. Durability of the Endurant stent graft in patients undergoing endovascular abdominal aortic aneurysm repair. J Vasc Surg 2014; 60:1125–31.
29.Oliveira NFG, Bastos Goncalves FM, de Vries, J, et al. Mid-term results of EVAR in severe proximal aneurysm neck angulation. Eur J Vasc Endovasc Surg 2015;49:19–27.
30.Singh MJ, Fairman R, Anain P, et al. Final results of the Endurant stent graft system in the united states regulatory trial. J Vasc Surg 2016;64:55–62.
31.‘t Mannetje YW, Cuypers PWM, Saleem BR, et al. Comparison of midterm results for the talent and endurant stent graft. J Vasc Surg 2017;66:735–42. 32.Deery SE, Shean KE, Pothof AB, et al. Three-year results of the Endurant stent graft system post approval study. Ann Vasc Surg 2018 [Epub ahead of print] 33.van Keulen JW, de Vries JP, Dekker H, et al. One-year multicenter results of 100 abdominal aortic aneurysm patients treated with the Endurant stent graft. J Vasc Surg 2011;54:609–15.
34.Rödel SGJ, Zeebregts CJ, Huisman AB, et al. Results of the Anaconda endovascular graft in abdominal aortic aneurysm with a severe angulated infrarenal neck. J Vasc Surg 2014;59:1495–501.
35.Freyrie A, Gallitto E, Gargiulo M, et al. Proximal aortic neck angle does not affect early and late EVAR outcomes: An Anaconda™ Italian registry analysis. J Cardiovasc Surg (Torino) 2014;55:671–7.
36.Maudet A, Daoudal A, Cardon A, et al. Endovascular treatment of infrarenal aneurysms: Comparison of the results of secondand third-generation stent grafts. Ann Vasc Surg 2016;34:95–105.
37.Cayne NS, Adelman MA, Veith FJ. Current status of investigational devices for EVAR: Similarities and differences. Semin Vasc Surg 2009;22:127–31.
38.Brown LC, Greenhalgh RM, Kwong GP, et al. Secondary interventions and mortality following endovascular aortic aneurysm repair: Device-specific results from the UK EVAR trials. Eur J Vasc Endovasc Surg 2007;34:281–90.
39.Nevala T, Biancari F, Manninen H, et al. Finnish multicenter study on the midterm results of use of the Zenith stent-graft in the treatment of an abdominal
aortic aneurysm. J Vasc Interv Radiol 2009;20:448–54. 40.Hiramoto JS, Reilly LM, Schneider DB, et al. Long-term outcome and reintervention after endovascular abdominal aortic aneurysm repair using the Zenith stent graft. J Vasc Surg 2007;45:461–6. 41.Sobocinski J, Briffa F, Holt PJ, et al. Evaluation of the Zenith low-profile abdominal aortic aneurysm stent graft. J Vasc Surg 2015; 62:841–7.
42.Goodney PP, Fillinger MF. The effect of endograft relining on sac expansion after endovascular aneurysm repair with the original-permeability Gore Excluder abdominal aortic aneurysm endoprosthesis. J Vasc Surg 2007;45:686–93.
43.Krajcer Z, Rajan L, Thota V, et al. Lowpermeability Gore Excluder device versus the original in abdominal aortic aneurysm size regression. Tex Heart Inst J 2011;38: 381–5.
44.Haider SE, Najjar SF, Cho JS, et al. Sac behavior after aneurysm treatment with the Gore Excluder low-permeability aortic endoprosthesis: 12-month comparison to the original excluder device. J Vasc Surg 2006;44: 694–700.
45.Katsargyris A, Mufty H, Wojs R, et al. Single-centre experience with the Gore C3 Excluder stent-graft in 200 consecutive patients. J Cardiovasc Surg (Torino). 2016; 57:485–90.
46.Loa J, Dubenec S, Cao P, et al. The Gore global registry for endovascular aortic treat-ment: Objectives and design. Ann Vasc Surg 2016;31:70–6.
47.Howard DPJ, Marron CD, Sideso E, et al. Influence of proximal aortic neck diameter on durability of aneurysm sealing and overall survival in patients undergoing endovascular aneurysm repair. real world data from the Gore global registry for endovascular aortic treatment (GREAT). Eur J Vasc Endovasc Surg 2018. [Epub ahead of print].
48.EVAR trial participants. Endovascular aneurysm repair and outcome in patients unfit for open repair of abdominal aortic aneurysm (EVAR trial 2): Randomised controlled trial. The Lancet 2005;365:2187–92. 49.Bastos Goncalves F, de Vries JP, van Keulen JW, et al. Severe proximal aneurysm neck angulation: Early results using the endurant stentgraft system. Eur J Vasc Endovasc Surg 2011;41:193–200.
50.Makaroun MS, Tuchek M, Massop D, et al. One year outcomes of the United States regulatory trial of the endurant stent graft system. J Vasc Surg 2011;54:601–8.
